Venture capital (VC) firms investing in life science companies are gathering one after another in Nihonbashi district in Tokyo, creating a life science ecosystem where startups and VC firms converge.
In response, LINK-J has launched the "Let's Talk with VCs" series, inviting key figures from VC firms to discuss the latest trends and thoughts on a specific theme for each session.
In this forth session, DCI Partners Co., Ltd. (“DCIP”), which manages one of Japan’s largest bio-specialized funds, will talk about its unique, among other Japan VC players, investments in Taiwan that have been implementing since 2015. Former vice minister of Taiwan government, who has strong ties with Taiwanese biotech industry, and Taiwan local biotech companies will also appear to give in-depth speeches about the attractiveness of investing Taiwan.
Language:Jpanese/English
*English captions are available (you can choose to turn them on or off).
*Please note that LINK-J is not responsible for any errors or omissions in the captions.
How to use captions: Managing and viewing closed captioning
DCIP will give presentations in person and the others online.
Date and Time:
Wed, Dec 7, 5:00pm - 7:00pm (JST)
Venue:
- In-person：GLOBAL LIFESCIENCE HUB Confernce Room
- Virtual：Zoom Webinar
Register here!
(Opens an external site)
Program
| Time | Agenda |
| 16:45 | Door open |
| 17:00-17:05 | Welcome LINK-J |
| 17:05-17:20 | Presentation -“The status quo of Taiwan biotech industry” Taipei Medical University Dr.Wen-Chang Chang,Director Language: Japanese |
| 17:20-17:25 | Presentation -「DCIパートナーズの台湾投資戦略について」 DCI Partners Co., Ltd. Ms. Yuka Niimi,Associate Director Language: Japanese |
| 17:25-18:25 | Company introduction |
| 17:25-17:40 |
新旭生技 Aprinoia Therapeutics Inc. Mr. Masaomi Miyamoto,Vice President Language: Japanese |
| 17:40-17:55 | 瑞格國際 REGiMMUNECo, Ltd. Mr. Kenzo Kosuda,CEO & President Language: Japanese |
| 17:55-18:10 | 仲恩生醫 Steminent Biotherapeutics Inc. Mr.Kevin Chih-Yuan Ho,Director of Clinical and Business Development Language: English |
| 18:10-18:25 | 宇康生科 Aprevent Medical Inc. Dr.Guan-Min Ho MD, PhD,Chief Executive Officer Language: English |
| 18:25-18:35 | Presentation -「台湾での投資実務、及び、台湾バイオテク企業のEXIT環境について」 DCI Partners Co., Ltd. Mr. Satoshi Motomura,President of Taiwan Office Language: Japanese |
| 18:35-18:55 | Q&A |
| 18:55-19:00 | Closing remarks - LINK-J |
| 19:00‐19:30 | Networking time [In-person only] |
| Biographies | |
 |
Dr.Wen-Chang Chang Director,Taipei Medical University (Education) Taipei Medical College, Taipei, Taiwan (1965-1969) Major in Pharmacy; Bachelor of Pharmacy degree awarded University of Tokyo, Faculty of Pharmaceutical Sciences, Tokyo, Japan (1973-1976) Major in Physiological Chemistry; Ph.D. awarded (Previous Experience) Visiting Fellow, Gerontology Research Center, National Institute on Aging, NIH, Baltimore, Maryland, U.S.A. (1976/10-1978/12) Visiting Scientist, College of Pharmacy, University of Kentucky, Lexington, Kentucky, U.S.A. (1981/09-1983/09) Professor, Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, Taiwan (1983-2011) Visiting Scholar, Department of Biochemistry, Tokushima University School of Medicine (Professor Shozo Yamamoto), Tokushima, Japan (1991/11-1992/01) Visiting Scholar, Department of Biochemistry, Kobe University School of Medicine (Professor Yasutomi Nishizuka), Kobe, Japan (1992/02-11) Visiting Scholar, William Harvey Research Institute (Director Sir John R. Vane), London, U. K. (1997/06-09) General Director, Department of Life Sciences, National Science Council, Taiwan (1999/11-2001/07) Dean, College of Bioscience and Biotechnology, National Cheng Kung University (2005/08-2008/05) Deputy Minister, National Science Council (2008/05-2011/04) Chairman, Board of Trustees, Taipei Medical University (2014/08-2022/07) |
 |
Ms.Yuka Niimi Associate Director, DCI Partners Co., Ltd. 新卒後、投資銀行の投資部門にてPEおよびディストレスト投資業務に従事。DCIパートナーズでは、日台の製薬・バイオ関連投資業界における4年超の投資経験を有し、新規投資先の開拓から財務・法務面のデューデリジェンスやバリュエーション評価、M&AおよびIPOによるEXITまで実施。その他、ベンチャークリエーション投資先の経営管理や、運用する2号ファンド（153億円）のファンドレイズ、コーポレート広報業務なども担当。 |
 |
Mr. Masaomi Miyamoto Vice President,新旭生技 Aprinoia Therapeutics inc. (職歴) １９７５年４月 武田薬品工業株式会社入社、中央研究所医薬研究所に配属 １９８７年１０月 客員研究員として米国ジョンズ・ホプキンス大学医学部 精神科（Joseph Coyle教授）に留学 ２００２年４月 創薬研究本部創薬第一研究所所長 ２００３年４月 創薬研究本部創薬第二研究所所長 ２００５年１０月 医薬研究本部創薬第三研究所所長 ２００６年６月 医薬開発本部本部長 ２００６年６月 TGRD Chairman兼務 ２００８年４月 武田バイオ開発センター株式会社会長兼務 ２０１１年6月 生化学工業常務取締役、研究開発本部長 ２０１８年１月 APRINOIA Therapeutics株式会社副社長 (役職および所属学会) 日本薬理学会学術評議員（1985-2015）、日本薬理学会理事(2006-2009)、日本薬理学会名誉会員（2015-）、日本神経精神薬理学会評議員（1986-2015）、日本神経精神薬理学会功労会員（2015-）、老化促進モデルマウス研究協議会評議員（1995-）、老化促進モデルマウス学会監査（2015-）、米国神経科学会会員(1987-2009）、JAPIC理事（2006-2009）、IMIC理事（2008-2009）、日本抗生物質学術協議会理事（2006-2009）、日本PGxデータサイエンスコンソーシアム（JPDSC）会長（2009-2010）、代謝異常治療研究基金理事（2006-2010）、慶応大学医学部客員教授（2002-2004）、東京大学薬学部非常勤講師（2002-2017）、九州大学薬学部非常勤講師(2009－2012)、福岡大学客員教授（2010－2013）、Marquis Who's Who in the World (1999-) 他 武田薬品における意識障害治療薬ヒルトニン、脳代謝改善薬アバン、睡眠障害 治療薬ロゼレムの研究開発 生化学工業における変形性膝関節症治療薬Gelone, 椎間板ヘルニア治療薬ヘル二コアの開発、変形性膝関節症治療薬SI-613の開発 学術論文：93報 執筆：11報 国際特許：43件 |
 |
Mr. Kenzo Kosuda CEO & President, 瑞格國際 REGiMMUNECo, Ltd. 1989年4月 東洋信託銀行（現三菱UFJ信託銀行）入行 1992年10月 監査法人ト－マツ（現有限責任監査法人トーマツ）入所 1997年9月 中央クーパース・アンド・ライブランド・アドバイザーズ入社 1999年6月 スパークス投資顧問（現スパークス・グループ）入社 2013年5月 株式会社レグイミューン入社 2013年12月 同取締役就任 2016年7月 同代表取締役社長就任(現任) 2018年6月 瑞格國際生技股份有限公司(REGiMMUNE Limited) 事長暨執行長就任（現任） |
 |
Mr.Kevin Chih-Yuan Ho Director of Clinical and Business Development, 仲恩生醫 Steminent Biotherapeutics Inc. Dr. Ho joined SBI in 2012 and leads the Clinical and Business Development. He is responsible for SBI’s out licensing collaborations in Japan and Korea and the success of the granted Orphan Drug Designation of SBI’s cell product, Stemchymal®, for Spinocerebellar Ataxia treatment in the US and Japan. He has more than 15 years of experience in stem cell science and business development. Dr. Ho obtained his Ph.D degree in Biomedical Engineering from University College London, UK. |
 |
Dr.Guan-Min Ho MD, PhD Chief Executive Officer, 宇康生科 Aprevent Medical Inc. I Graduated as a medical doctor (MD) and received my PhD degree in "Clinical Pathology" at Medical University of Vienna in 1998. During the educational period, I also worked as a researche fellow and tutor at the Clinical Pathology Department before starting my residency training in internal medicine and otorhinolaryngology at Chang-Gun Memorial Hospital and Mackay Memorial Hospital, respectively. After my board certification in otorhinolaryngology head & neck surgery in 2004 I worked as an attending physician in medical centers and lectured as assistant professor at National Taipei University of Nursing and Health Sciences. During my clinical practice, I never lost my passion for basic research, therefore I founded with like-minded partners in the year of 2013"APrevent Medical" and dedicated my work mainly in the field of laryngology and voice disorders. Though being confronted with lots of challenges, incl. the COVID pandemic, our first product "Vocal Implant System" is highly praised by KOLs and is successfully launched on the EU market. Our second project is dedicated to improve the intelligibility of dysarthric patients and still under development. |
 |
Mr. Satoshi Motomura President of Taiwan Office,DCI Partners Co., Ltd. (経歴) 2004年3月 上智大学外国語学部卒 2004年4月 大和企業投資株式会社 入社 2008年9月 台湾VC・和通国際（股）に出向 2014年9月 大和企業投資株式会社 台北事務所所長 就任（現職） 2020年8月 台湾VC・和通国際（股）取締役 就任（現職） 2022年4月 DCI Vietnam Fund III Management Co., Ltd. 取締役 就任（現職） (他) 2018年4月～現在 日経バイオテク コラムニスト 「World Trend Asia」や「本村聡士の台湾バイオ最前線」でコラム連載中 2022年3月～現在 台湾大手紙・経済日報 コラムニスト |
Participation fee
Free
Capacity
In-person: 40 people
*We reserve the right to change the event as a completely virtual format due to government requests or the status of the spread of COVID-19 infection. In such cases, please watch the webinar even if you have registered as an in-person attendee.
Virtual: 1000 people
Organizer
Organizer：Life Science Innovation Network Japan (LINK-J)
Contact
contact＠link-j.org
